Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
about
Cost-effectiveness of pneumococcal vaccination strategies for the elderly in KoreaCost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil.A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.Role of vaccination in the sustainability of healthcare systems.Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.Theory and strategy for Pneumococcal vaccines in the elderly.Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?The full benefits of adult pneumococcal vaccination: A systematic review.Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
P2860
Q33675229-848F72F4-8BDC-4CC5-9487-19FB03C84ECCQ35675286-ABAC8303-7A73-4A4C-8285-A1D38559E725Q36015061-A202BFBD-6F0E-4B7A-8937-6F935E2B321BQ36571135-9C0D52DC-A31B-4697-8F19-9AC5C2DD96BFQ36714717-C28E3033-CB5C-4AAA-A0D2-F2485B578CBDQ37309186-9E2AC080-1F57-4A40-9C1F-592D86E8B827Q37309215-4DD5DDD2-EE9E-448B-9AE3-C6141D5F4B0EQ38620718-03832825-1557-4780-8889-724771968D2FQ47098784-D8AC8AD3-E103-4981-B14B-BA62B6D3C5B0Q57211903-A63B0D5F-935A-436A-BF3D-1DE3A367E0A5
P2860
Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Cost-effectiveness of vaccinat ...... l conjugate vaccine in the UK.
@en
type
label
Cost-effectiveness of vaccinat ...... l conjugate vaccine in the UK.
@en
prefLabel
Cost-effectiveness of vaccinat ...... l conjugate vaccine in the UK.
@en
P2093
P2860
P1476
Cost-effectiveness of vaccinat ...... l conjugate vaccine in the UK.
@en
P2093
Aline Gauthier
Sam Keeping
Stuart Carroll
Yiling Jiang
P2860
P304
P356
10.1586/14737167.2014.950232
P577
2014-09-05T00:00:00Z